麻豆国产精品一二三在线观-麻豆国产精品一二三在线观看-麻豆国产精品一区二区-麻豆国产精品永久免费视频-麻豆国产巨作av剧情-麻豆国产蜜桃臀视频在线观看

冰島阿特維斯（Actavis）   
全球領先的仿制藥制造商Actavis Inc(NYSE：ACT)(原華生制藥)
2012年10月，原華生制藥公司(Watson Pharmaceuticals)斥資56億美元收購了瑞士制藥商Actavis Group之后，并將公司名改為Actavis Inc，將股票代碼從“WPI”改為“ACT”。

冰島著名Actavis生物制藥公司成立于1956年，于2005年并購國際制藥公司Alpharma后，已成為世界上第四大生物制藥公司。該公司是冰島第一大制藥企業，現有雇員10000多名。是冰島證券交易所上市企業，目前市值約20億美元。該公司在32個國家有經營業務，生產和銷售650多種藥品，300余種新藥正在研發中。市場分布以歐美為主，05-06年通過并購，進入并占據俄羅斯、羅馬尼亞等東歐市場的一定份額。主要產品：心血管藥物系列、中樞神經藥物系列、抗感染藥物系列等
阿特維斯是世界領先的普藥企業之一，專注于普藥的研發、制造和銷售。1956年成立于冰島，當時的名稱為Pharmaco，2004年更名為Actavis。1997年于冰島股票交易所登記上市，1999年建立國際發展戰略,向國際市場進軍，實施一系列收購行動，到2005年成功并購美國雅來的人類普藥業務后公司已經躍居全球第四大普藥企業。2006年公司的市場價值約30億歐元（38億美元），2004年營業額為12億歐元，預計2007年營業額將達到15.5億歐元。公司目前在30多個國家經營業務，雇員超過11000名，擁有240 億片劑的生產能力，在市場上銷售600多種產品，主要覆蓋：中樞神經、心血管、消化、代謝、骨骼肌肉、抗感染、呼吸系統及其它類別。在行業內我們著稱于：成長最快的公司，定位一流品質普藥市場，注冊最多新產品的公司，成功并購（最多）的紀錄，具有挑戰性同時又令人興奮的工作環境。因為阿特維斯的愿景是成為國際普藥市場上研發，制造和銷售合格產品的旗艦。ACTAVIS就是：ACTA=Action行動 + VIS=Strength力量，Actavis還代表：Vital 有生命力的，Ambitious 有雄心的，Speedy 迅速的，Decisive 果斷的，Innovative 創新的，Pro-active 積極主動的 ，Reliable 可信賴的 ，Modern 現代化的，International 國際化的 。


Actavis Foshan is an important manufacturing site in Asia. The Guangdong plant employs 300 staff producing antibiotics and other products for use in the treatment of the digestive and cardiovascular system. Dosage forms include tablet, soft gel capsule, hard capsule, oral solution, dry suspension, ointments and liniments.

The Actavis (Foshan) Pharmaceutical Co., Ltd. is a joint venture between the Actavis Group and Foshan Chanbende Development Co., Ltd.

The Actavis Group is one of the world’s leading players in the development, manufacture and sale of high-quality generic pharmaceuticals. The successful integration of a number of acquisitions has helped position Actavis among the world’s largest companies in the industry. Founded in 1956, the Group has more than 10,000 employees operating in about 40 countries around the globe. Its headquarters are in Iceland.

The Company has modern development and manufacturing facilities in Europe, the US and Asia. The plants produce a variety of medicines in different formulations including tablets, capsules, injectables, suppositories, sprays, steriles, powders, oral liquids and semi-solids.

Product portfolio

Actavis offers one of the broadest product portfolios and strongest pipelines in the generics industry:

Around 830 products on the market
Over 350 products under development and pending registration
Products registered in more than 60 countries
Over 660 product and market launches in Group markets in 2008

Future opportunities

An extensive network of sales and marketing offices enables effective market penetration, positioning the Group strongly in the world’s largest markets for generic pharmaceuticals. Strategic acquisitions, the opening of new sales offices and intensive investment in the development of generic pharmaceuticals are fuelling the growth of Actavis and have positioned the Group to take advantage of future opportunities.

The Group remains committed to leading the consolidation of a still fragmented industry through strategic acquisitions and to driving further organic growth through innovative product launches, penetration of new markets and regulatory approvals of new generic pharmaceuticals.

Actavis continues to invest heavily in research and development, pursuing a determined first-to-market strategy and positioning itself to take full advantage of future opportunities.